Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Up 6.1% in November

Avenue Therapeutics, Inc. (NASDAQ:ATXI) saw a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 46,800 shares, an increase of 6.1% from the November 15th total of 44,100 shares. Currently, 2.7% of the company’s shares are sold short. Based on an average daily volume of 43,900 shares, the days-to-cover ratio is presently 1.1 days.

Avenue Therapeutics Stock Performance

ATXI stock traded down $0.06 during trading on Tuesday, hitting $1.74. 24,989 shares of the company traded hands, compared to its average volume of 57,505. The company has a 50-day moving average of $2.05 and a 200-day moving average of $2.66. Avenue Therapeutics has a 1 year low of $1.60 and a 1 year high of $26.47. The firm has a market capitalization of $3.57 million, a PE ratio of 0.09 and a beta of -0.20.

Institutional Trading of Avenue Therapeutics

An institutional investor recently bought a new position in Avenue Therapeutics stock. Armistice Capital LLC acquired a new position in Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 75,000 shares of the company’s stock, valued at approximately $262,000. Armistice Capital LLC owned 7.97% of Avenue Therapeutics as of its most recent filing with the Securities and Exchange Commission. 17.34% of the stock is currently owned by institutional investors and hedge funds.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.